Zi Bo Dong

Corporate Officer/Principal en Jumpcan Pharmaceutical Co. Ltd. .

54 años

Health Technology

Perfil

Zi Bo Dong is currently the Deputy GM & Head of Drug Research Institute at Jumpcan Pharmaceutical Co. Ltd.
Prior to this, he worked as the Director & Deputy General Manager at Hubei Jumpcan Pharmaceutical Co., Ltd.

Cargos activos de Zi Bo Dong

Empresas	Cargo	Inicio
Jumpcan Pharmaceutical Co. Ltd. Jumpcan Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hubei Jumpcan Pharmaceutical Co., Ltd., Jumpcan Pharmaceutical Co. Ltd. is a pharmaceutical company based in Taixing, China. The Chinese company offers a range of products including mouthwash, cough medicine, and pain relief ointments. The CEO of the company is Long Xiang Cao. Jumpcan Pharmaceutical Co. was acquired by Hubei Jumpcan Pharmaceutical Co., Ltd. from Jiangsu Jichuan Holdings Group Co. Ltd. on December 20, 2013 for $911.88 million.	Corporate Officer/Principal	-

Todos los cargos activos de Zi Bo Dong

Antiguos cargos conocidos de Zi Bo Dong.

Empresas	Cargo	Fin
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	Director/Miembro de la Junta	28/07/2018

Ver el detalle de la experiencia de Zi Bo Dong.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Zi Bo Dong.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	Health Technology

Empresas privadas	1
Jumpcan Pharmaceutical Co. Ltd. Jumpcan Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hubei Jumpcan Pharmaceutical Co., Ltd., Jumpcan Pharmaceutical Co. Ltd. is a pharmaceutical company based in Taixing, China. The Chinese company offers a range of products including mouthwash, cough medicine, and pain relief ointments. The CEO of the company is Long Xiang Cao. Jumpcan Pharmaceutical Co. was acquired by Hubei Jumpcan Pharmaceutical Co., Ltd. from Jiangsu Jichuan Holdings Group Co. Ltd. on December 20, 2013 for $911.88 million.	Health Technology